

Perioperative Management of Anticoagulation

2020-2023

References

1. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. *Am J Med.* 1998;104:332-338.
2. Heit JA, Cohen AT, Anderson FA. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. *Blood.* 2005;106:910a.
3. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica.* 2007;92:199-205.
4. Kearon C. Natural history of venous thromboembolism. *Circulation.* 2003;107(23 suppl 1):I22-130.
5. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet.* 2003;362:523-526.
6. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. *Arch Intern Med.* 2010;170:1710-1716.
7. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. *N Engl J Med.* 1997;336:1506-1511.
8. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *N Engl J Med.* 1999;340:901-907.
9. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. *JAMA.* 2009;301:2472-2485.
10. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. *Blood.* 2009;113:5314-5322.
11. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood.* 2002;100:3484-3488.
12. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. *Thromb Haemost.* 2002;88:407-414.
13. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141:e326s-350s.
14. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. *Thromb Res.* 2002;108:3-13.
15. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA.* 2001;285:2864-2870.
16. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA.* 2001;285:2370-2375.

17. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. *Arch Intern Med.* 1994;154:1449-1457.
18. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. *Arch Intern Med.* 1987;147:1561-1564.
19. Kaplan RC, Tirschwell DL, Longstreth WT, Jr, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. *Neurology.* 2005;65:835-842.
20. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). *Chest.* 2008;133(6 suppl):546s-592s.
21. Lopes RD, Crowley MJ, Shah BR, et al. Comparative Effectiveness Review Number 123: Stroke Prevention in Atrial Fibrillation. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services; 2013.
22. Whitlock RP, Sun JC, Fremes SE, et al; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141:e576s-e600s.
23. Douketis JD, Spyropoulos AC, Kaatz S, et al; BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. *N Engl J Med.* Available at: <http://www.nejm.org/doi/full/10.1056/NEJMoa1501035>. Published: June 22, 2015 [Epub ahead of print].
24. Kaatz S, Douketis JD, Zhou H, et al. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. *J Thromb Haemost.* 2010;8:884-890.
25. Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: a systematic review and meta-analysis of bleeding and thromboembolic rates. *Circulation.* 2012;126:1630-1639.
26. Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Circulation.* 2015;131:488-494.
27. Baudet EM, Puel V, McBride JT, et al. Long-term results of valve replacement with the St. Jude Medical prosthesis. *J Thorac Cardiovasc Surg.* 1995;109:858-870.
28. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. *N Engl J Med.* 1995;333:11-17.
29. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical valve prostheses. *Circulation.* 1994;89:635-641.
30. Elkayam U, Golland S. The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves. *J Am Coll Cardiol.* 2012;59:1116-1118.
31. Brouwer JL, Lijfering WM, Ten Kate MK, et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. *Thromb Haemost.* 2009;101:93-99.
32. University of Washington Medical Center Anticoagulation Clinics. Suggestions for anticoagulation management before and after dental procedures. Available at: <https://depts.washington.edu/anticoag/home/content/suggestions-anticoagulation-management-and-after-dental-procedures>. Accessed September 4, 2019.
33. Nematullah A, Alabousi A, Blanas N, et al. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. *J Can Dent Assoc.* 2009;75:41.
34. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. *J Am Dent Assoc.* 2000;131:77-81.

35. Jamula E, Anderson J, Douketis JD. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. *Thromb Res.* 2009;124:292-299.
36. Mehta V, Mueller PS, Gonzalez-Arriaza HL, et al. Safety of electroconvulsive therapy in patients receiving long-term warfarin therapy. *Mayo Clin Proc.* 2004;79:1396-1401.
37. Eisen GM, Baron TH, Dominitz JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. *Gastrointest Endosc.* 2002;55:775-779.
38. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. *N Engl J Med.* 2013;368:2084-2093.
39. Ghanbari H, Phard WS, Al-Ameri H, et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. *Am J Cardiol.* 2012;11:1482-1488.
40. Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. *Ann Pharmacother.* 2006;40:2205-2210.
41. Jeske AH, Suchko GD, ADA Council on Scientific Affairs and Division of Science, Journal of the American Dental Association. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment. *J Am Dent Assoc.* 2003;134:1492-1497.
42. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. *Ann Intern Med.* 1995;122:40-42.
43. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood.* 2005;106:2710-2715.
44. Lazio BE, Simard JM. Anticoagulation in neurosurgical patients. *Neurosurgery.* 1999;45:838,847; discussion 847-848.
45. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. *Ann Intern Med.* 2007;146:184-187.
46. Enoxaparin [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2007.
47. Dalteparin [package insert]. New York, NY: Pfizer Inc; 2007.
48. Tinzaparin [package insert]. Ballerup, Denmark: Leo Pharmaceutical Products; 2008.
49. Barras MA, Duffull SB, Atherton JJ, et al. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. *Ther Drug Monit.* 2010;32:482-488.
50. Lazo-Langner A, Lang ES, Douketis J. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. *Crit Care.* 2013;17:230.
51. Quality Improvement Organizations. Managing Anticoagulation in the Periprocedural Period: Guidelines from the Periprocedural Task Force of the New York State Anticoagulation Coalition. Available at: http://qio.ipro.org/wp-content/uploads/2012/12/MAP2014_5_01.pdf. Published May 1, 2014.
52. Tripodi A, Palareti G. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. *J Intern Med.* 2012;271:554-565.
53. Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves [FDA Drug Safety Communication]. Silver Spring, MD: US Food and Drug Administration; December 19, 2012.
54. Sié P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on

- Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. *Arch Cardiovasc Dis.* 2011;104:669-676.
55. Levy JH, Faraoni D, Spring JL, Douketis JD, et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. *Anesthesiology.* 2013;118:1466-1474.
56. Mulder FL, Candeloro M, Kamphuisen PW, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. *Haematologica.* 2019; 104: 1277-1287
57. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. *Blood Adv.* 2018;27: 3257-3291.
58. Baumgartner C, de Kouchkovsky I, Whitaker E, et al. Perioperative Bridging in Patients with Venous Thromboembolism: A Systematic Review. *Am J Med.* 2019;132:722-732
59. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest.* 2018;154:1121-1201.
60. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guidelines for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and Heart Rhythm Society. *J Am Coll Cardiol.* 2019;9:104-132
61. López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulation for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. *BMJ.* 2017;359:j5058
62. Friberg L, Rosengvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J.* 2012;33:1500-1510
63. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation: A Report of the American college of Cardiology Clinical Expert Consensus Document Task Force. *J Am Coll Cardiol.* 2017;69: 871-898
64. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circ.* 2017;135: 1159-1195
65. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a Report on the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;63: 57-185
66. Raskob, G. E. et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. *N. Engl. J. Med.* 2018;378, 615–624.
67. Pollack, A. M. et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). *J. Clin. Oncol.* 2018; 36, 2017–2023.
68. Samuelson, B. T., Cuker, A., Siegal, D. M., Crowther, M. & Garcia, D. A. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. *Chest.* 2017; 151: 127–138.
69. Pollack, C. V., Jr et al. Idarucizumab for Dabigatran Reversal. *N. Engl. J. Med.* 2015; 373: 511–520.
70. Connolly, S. J. et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. *N. Engl. J. Med.* 2019;380 (14): 1326-35.
71. Douketis, J. D. et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. *JAMA Intern Med.* 2019;179, 1469–1478.

72. Burnett, A. E. et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. *J. Thromb. Thrombolysis*. 2016;41:206–232.
73. Peterson, J. J. & Hoehns, J. D. Administration of Direct Oral Anticoagulants Through Enteral Feeding Tubes. *J. Pharm. Technol.* 2016;32: 196–200.
74. Takeuchi, Y. et al. Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps. *Annals of Internal Medicine*. 2019;171, 229–237.